2562386-85-8

2562386-85-8 structure

Name: HDAC-IN-46
Chemical Name: HDAC-IN-46
CAS Number: 2562386-85-8
Molecular Formula: C₂₂H₃₀N₈O₂
Molecular Weight: 438.53
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2022-09-13 17:53:49
Modify Date: 2024-07-24 08:03:07
HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC50 value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC)[1].

Name	HDAC-IN-46

Description	HDAC-IN-46 (compound 12c) is a potent HDAC inhibitor with an IC50 value of 0.21 μM and 0.021 μM for HDAC1 and HDAC6, respectively. HDAC-IN-46 upregulates p-p38, and downregulates Bcl-xL and cyclin D1 in MDA-MB-231 cells. HDAC-IN-46 induces significant G2 phase arrest and apoptosis. HDAC-IN-46 can be used for researching triple-negative breast cancer (TNBC)[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC Signaling Pathways >> Epigenetics >> HDAC
Target	HDAC1:0.21 μM (IC50) HDAC6:0.021 μM (IC50)
In Vitro	HDAC-IN-46 (compound 12c) has antiproliferative activity against MDA-MB-231, A549 and MCF-7 with IC50s of 88.46±10.5 μM, 83.34 ± 15.5 μM and 21.4±3.7 μM, respectively[1]. HDAC-IN-46 (5, 12.5 and 25 μM; 24 h) causes concentration-dependent upregulation of p-p38 and downregulation of Bcl-xL and cyclin D1 in MDA-MB-231 cells[1]. HDAC-IN-46 (12.5 and 25 μM; 48 h) induces significant G2 phase arrest and apoptosis[1]. Western Blot Analysis[1] Cell Line: MDA-MB-231 cells Concentration: 5, 12.5 and 25 μM Incubation Time: 24 h Result: Caused concentration-dependent upregulation of p-p38 and downregulation of Bcl-xL and cyclin D1. Cell Cycle Analysis[1] Cell Line: MDA-MB-231 cells Concentration: 12.5 and 25 μM Incubation Time: 48 h Result: Induced significant G2 phase arrest and apoptosis.
References	[1]. Wu B, et al. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity. Bioorg Med Chem. 2020 Mar 15;28(6):115345.

Molecular Formula	C₂₂H₃₀N₈O₂
Molecular Weight	438.53

2562386-85-8	2410542-97-9
1621154-88-8	934828-12-3
2653339-26-3	1018673-42-1
1239610-44-6	2454024-18-9
1809163-24-3	2756809-34-2
1805357-24-7	1447963-00-9
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4